Key Points
- Insider purchase: enGene insider William Grossman bought 5,102 shares at an average price of $1.97, investing approximately $10,050.94 and establishing a direct ownership stake of the same amount.
- Weak financial performance: enGene reported a quarterly loss of $0.47 per share, missing analyst expectations of a $0.43 loss. Analysts expect a full-year loss of approximately $1.81 per share.
- Mixed market outlook: Analysts maintain a consensus “Hold” rating with a $11.05 price target, while the stock recently traded near $1.92 after reaching a 52-week range of $1.40 to $12.25.
enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) insider William Grossman bought 5,102 shares of the firm's stock in a transaction dated Tuesday, September 22nd. The shares were acquired at an average price of $1.97 per share, for a total transaction of $10,050.94. Following the transaction, the insider directly owned 5,102 shares in the company, valued at approximately $10,050.94. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
enGene Price Performance
enGene stock opened at $1.92 on Friday. The company's fifty day moving average price is $1.83 and its 200 day moving average price is $3.39. enGene Holdings Inc. has a 1 year low of $1.40 and a 1 year high of $12.25. The stock has a market capitalization of $128.68 million, a P/E ratio of -1.70 and a beta of -0.28. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.21 and a current ratio of 10.21.
enGene (NASDAQ:ENGN - Get Free Report) last issued its quarterly earnings results on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.04). As a group, equities research analysts anticipate that enGene Holdings Inc. will post -1.81 earnings per share for the current fiscal year.
Analysts Set New Price Targets
ENGN has been the subject of several research analyst reports. Citizens Jmp restated a "market perform" rating on shares of enGene in a research report on Wednesday, September 9th. Morgan Stanley cut enGene from an "equal weight" rating to an "underweight" rating and set a $3.00 price objective on the stock. in a report on Thursday, June 18th. HC Wainwright reiterated a "buy" rating and set a $4.00 price objective on shares of enGene in a research note on Tuesday, September 8th. Citigroup reiterated a "market perform" rating on shares of enGene in a research note on Wednesday, September 9th. Finally, Wall Street Zen raised enGene from a "strong sell" rating to a "sell" rating in a report on Saturday, August 15th. Four investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $11.05.
View Our Latest Analysis on ENGN
Institutional Investors Weigh In On enGene
Hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP acquired a new position in enGene during the first quarter worth about $251,000. Sei Investments Co. purchased a new stake in enGene during the 1st quarter valued at about $409,000. Renaissance Technologies LLC raised its holdings in enGene by 651.1% in the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company's stock valued at $1,063,000 after acquiring an additional 135,318 shares during the last quarter. SR One Capital Management LP purchased a new position in enGene in the 2nd quarter worth approximately $1,293,607. Finally, Elmind Capital LP acquired a new position in shares of enGene during the 4th quarter worth approximately $1,896,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.
enGene Company Profile
(
Get Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
